TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20833988

Group type: EXPERIMENTAL
Intervention: Low glycemic index (GI) dietary advice
Number of subjects: 104

Group type: COMPARATOR
Intervention: Conventional carbohydrate exchange (CCE) dietary advice
Number of subjects: 104
Study: 18280116

Group type: EXPERIMENTAL
Intervention: 100mg immediate-release (IR) tablets
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 250mg controlled-release (CR) tablets
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 500mg IR BID
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 1250mg CR QD
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 15699835

Group type: EXPERIMENTAL
Intervention: Cessation of enteral tube feeding for RV >400 mL in study patients
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cessation of enteral tube feeding for RV >200 mL in controls
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Percutaneous endoscopic gastrostomy tubes
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nasogastric tubes
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: RV <150 mL
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: RV >400 mL
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: RV >300 mL
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: RV >200 mL
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: RV >150 mL
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Blue food coloring detection
Number of subjects: 40
Study: 12426766

Group type: EXPERIMENTAL
Intervention: Novel drug delivery system with average particle size between 1-150 microns
Number of subjects: 0

Group type: COMPARATOR
Intervention: Microemulsion system
Number of subjects: 0
Study: 9504848

Group type: EXPERIMENTAL
Intervention: Postoperative responses after vestibular nerve section
Number of subjects: 9

Group type: COMPARATOR
Intervention: Preoperative responses
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Follow-up responses
Number of subjects: 9
Study: 7814484

Group type: EXPERIMENTAL
Intervention: Monovalent influenza A/Taiwan/1/86 (H1N1) virus HA, doses ranging from 0 to 405 micrograms per dose
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Trivalent HA vaccine containing A/H1N1, A/H3N2, and influenza B virus HA, doses ranging from 0 to 135 micrograms per strain, 0 to 405 micrograms per dose
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Standard dose of commercial influenza vaccine (control group)
Number of subjects: 139
Study: 2528230

Group type: EXPERIMENTAL
Intervention: Intensive dynamic back extensor exercises (30 sessions over 3 months)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Alternative group with 1/5 of the treatment group's exercise program per session
Number of subjects: 105

Group type: COMPARATOR
Intervention: Alternative group with thermotherapy, massage, and mild exercise
Number of subjects: 105
Study: 29400990

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) using a POWERbreathe KH1 device, commenced at 50% maximum inspiratory pressure, with training load progressively increased
Number of subjects: 7
Study: 28611235

Group type: EXPERIMENTAL
Intervention: ivacaftor
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 27477305

Group type: EXPERIMENTAL
Intervention: OCT guided atherectomy with the Pantheris™ device
Number of subjects: 11
Study: 23983130

Group type: EXPERIMENTAL
Intervention: Intervention-2 (point-of-care decision support and parent outreach)
Number of subjects: 549

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 549
Study: 21901266

Group type: EXPERIMENTAL
Intervention: 1 set in lower-body exercises and 3 sets in upper-body exercises (1L-3UB)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 3 sets in lower-body exercises and 1 set in upper-body exercises (3L-1UB)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Training (both groups)
Number of subjects: 15
Study: 19874925

Group type: EXPERIMENTAL
Intervention: AMA1-C1/Alhydrogel + CPG 7909
Number of subjects: 24

Group type: COMPARATOR
Intervention: AMA1-C1/Alhydrogel
Number of subjects: 24
Study: 17803844

Group type: EXPERIMENTAL
Intervention: Paroxetine + Zolpidem (Group A, treated with paroxetine 10 ‐ 20 mg/d and zolpidem 10 mg/d for 4 weeks)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Paroxetine only (Group B)
Number of subjects: 229
Study: 15149563

Group type: EXPERIMENTAL
Intervention: FSH-mass
Number of subjects: 250

Group type: COMPARATOR
Intervention: FSH-bio
Number of subjects: 250
Study: 12139731

Group type: EXPERIMENTAL
Intervention: UKALL XI protocol with two 5‐d intensification blocks at 5 and 20 weeks and a third intensification at 35 weeks.
Number of subjects: 3617

Group type: EXPERIMENTAL
Intervention: UKALL XI protocol
Number of subjects: 3617

Group type: COMPARATOR
Intervention: UKALL X protocol
Number of subjects: 3617

Group type: EXPERIMENTAL
Intervention: Increased intensity of therapy
Number of subjects: 3617

Group type: EXPERIMENTAL
Intervention: Introduction of a third late intensification block
Number of subjects: 3617
Study: 9839627

Group type: EXPERIMENTAL
Intervention: Intralesional hyaluronidase (HD) pretreatment
Number of subjects: 9
Study: 8074012

Group type: EXPERIMENTAL
Intervention: Inhalation of cold air (−22 degrees C) during exercise
Number of subjects: 10

Group type: COMPARATOR
Intervention: Inhalation of thermoneutral air (22 degrees C) during exercise
Number of subjects: 10
Study: 2520633

Group type: EXPERIMENTAL
Intervention: Closed-loop control system (CLCS)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Manual control
Number of subjects: 45

Group type: COMPARATOR
Intervention: Computer-assisted control
Number of subjects: 45
Study: 766497

Group type: EXPERIMENTAL
Intervention: Nifurantin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulfaclomid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Target therapy as per antibiogram
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Blind early therapy with Nifurantin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simultaneous urine culture
Number of subjects: 0
Study: 31375458

Group type: EXPERIMENTAL
Intervention: Equation2 for active subjects: 33.08 + 2.41*(Velfinal) - 0.32*(F%) + 0.40*(VE_VT‐II) - 0.26*(BM) - 0.09*(HR_VT‐II)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Equation3 for sedentary subjects: 54.65 + 1.37*(T_VT‐II) + 8.24*(sex) - 1.26*(BMI) + 0.37*(VE_VT‐II) - 0.12*(HR_VT‐II)
Number of subjects: 181
Study: 31603939

Group type: EXPERIMENTAL
Intervention: Transcutaneous vagus nerve stimulation at different intensities (0.5, 1.0, 1.5 mA)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Set stimulation method
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Free stimulation method
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Active stimulation
Number of subjects: 61

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Higher stimulation intensities
Number of subjects: 61
Study: 28355926

Group type: EXPERIMENTAL
Intervention: Couple HIV testing and counseling (cHTC) attendance
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Male partner ART reminders
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Early disclosure of HIV-positive status
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: cHTC attendance among retained women
Number of subjects: 200
Study: 25781525

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Oral Contraceptive Pills (OCP)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control
Number of subjects: 22
Study: 23816952

Group type: COMPARATOR
Intervention: Inhalation of 0% CO2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhalation of 9% CO2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhalation of 17.5% CO2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhalation of 35% CO2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhalation of CO2 (all concentrations)
Number of subjects: 0
Study: 21414600

Group type: EXPERIMENTAL
Intervention: Final kissing balloon (KB) inflation, n = 124
Number of subjects: 293

Group type: COMPARATOR
Intervention: Isolated balloon after dilation (non-KB), n = 120
Number of subjects: 293
Study: 19290717

Group type: EXPERIMENTAL
Intervention: Personality disorder indication
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Grief severity
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: HIV symptoms
Number of subjects: 268
Study: 17005526

Group type: EXPERIMENTAL
Intervention: pH neutral, lactate-buffered, low GDP solution (balance)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional lactate‐buffered fluid (control)
Number of subjects: 50
Study: 15021447

Group type: EXPERIMENTAL
Intervention: Raloxifene (RAL) 60 mg/day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 50
Study: 11710752

Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone (0, 25, 50, 100 or 200 mg)
Number of subjects: 4
Study: 9278796

Group type: EXPERIMENTAL
Intervention: Topical diclofenac
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 20
Study: 2036070

Group type: EXPERIMENTAL
Intervention: Madopar HBS (sustained-release preparation)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Madopar M (standard preparation)
Number of subjects: 9
Study: 7225476

Group type: EXPERIMENTAL
Intervention: Fronto-frontal ECT
Number of subjects: 2

Group type: COMPARATOR
Intervention: Temporo-parietal ECT
Number of subjects: 2
Study: 31087825

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: mRNA (STMN1 and PPP1R9B)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: miRNA (miR‐3688 and miR‐5695)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Combined model (baseline depression severity, STMN1, and miR‐5695)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study: 27515070

Group type: EXPERIMENTAL
Intervention: Ustekinumab (Arm 1: immediate cessation of methotrexate; Arm 2: 4 weeks' overlap with decreasing methotrexate dose)
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 489
Study: 25856211

Group type: EXPERIMENTAL
Intervention: Letrozole or clomiphene citrate (up to five cycles)
Number of subjects: 710

Group type: COMPARATOR
Intervention: Both partners smoked
Number of subjects: 710

Group type: EXPERIMENTAL
Intervention: At least three sexual intercourse attempts over the previous 4 weeks
Number of subjects: 710
Study: 24916903

Group type: EXPERIMENTAL
Intervention: Lipocalin-2 treatment in microglia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lipocalin-2 treatment in astrocytes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conditioned media from lipocalin-2-treated astrocytes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conditioned media from lipocalin-2-treated microglia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neuronal expression of lipocalin-2
Number of subjects: 0
Study: 22541682

Group type: EXPERIMENTAL
Intervention: Alteplase push protocol (30 minutes)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Alteplase dwell protocol (30 minutes with additional 90 minutes if necessary)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Alteplase push protocol
Number of subjects: 82

Group type: COMPARATOR
Intervention: Alteplase dwell protocol
Number of subjects: 82
Study: 20215128

Group type: EXPERIMENTAL
Intervention: Gentamicin for 5 days plus doxycycline for 8 weeks
Number of subjects: 82

Group type: COMPARATOR
Intervention: Streptomycin for 2 weeks plus doxycycline for 45 days
Number of subjects: 82
Study: 18409186

Group type: EXPERIMENTAL
Intervention: Suspicious Digital Rectal Examination (DRE)
Number of subjects: 7280

Group type: EXPERIMENTAL
Intervention: Examiner variability in DRE interpretation
Number of subjects: 7280
Study: 15839376

Group type: EXPERIMENTAL
Intervention: Mention of organ scarcity and wait list demand statistics (n=66)
Number of subjects: 143

Group type: COMPARATOR
Intervention: No mention of organ scarcity and wait list demand statistics (n=77)
Number of subjects: 143
Study: 12219864

Group type: EXPERIMENTAL
Intervention: High self-esteem (HSE) participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low self-esteem (LSE) participants
Number of subjects: 0
Study: 10617237

Group type: EXPERIMENTAL
Intervention: Low-dose dopamine (LDD) at doses of 0-5 microg/kg/min
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low-dose dopamine (LDD)
Number of subjects: 20
Study: 8830834

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 12
Study: 1425818

Group type: EXPERIMENTAL
Intervention: Bromocriptine monotherapy
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Combination therapy (bromocriptine + levodopa) for 5 years
Number of subjects: 286

Group type: COMPARATOR
Intervention: Levodopa alone therapy for 5 years
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Bromocriptine alone followed by levodopa
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Maintained combination therapy for 5 years
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Levodopa alone followed by bromocriptine
Number of subjects: 286
Study: 4065703

Group type: EXPERIMENTAL
Intervention: Continuous intravenous morphine infusion
Number of subjects: 42

Group type: COMPARATOR
Intervention: Scheduled intramuscular morphine injections
Number of subjects: 42
Study: 30854694

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 29128486

Group type: EXPERIMENTAL
Intervention: Low dose sufentanil (bolus 0.25 µg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard dose sufentanil (bolus 0.5 µg/kg)
Number of subjects: 60
Study: 25496243

Group type: EXPERIMENTAL
Intervention: Immediate implant placement and immediate temporary restoration
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Immediate implant placement and early restoration
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Early implant placement and immediate temporary restoration
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Early implant placement and early restoration
Number of subjects: 48
Study: 24637202

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 122
Study: 22464936

Group type: EXPERIMENTAL
Intervention: Nature walk
Number of subjects: 20
Study: 20166789

Group type: EXPERIMENTAL
Intervention: HIV prevention motivation and behavioral self-efficacy
Number of subjects: 732

Group type: EXPERIMENTAL
Intervention: Peer and venue supports
Number of subjects: 732
Study: 16683122

Group type: EXPERIMENTAL
Intervention: CAOS (electromagnetic image guided surgery, NAVITRAK)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Freehand technique
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CAOS
Number of subjects: 12

Group type: COMPARATOR
Intervention: CT compared to dissection
Number of subjects: 12
Study: 16224147

Group type: EXPERIMENTAL
Intervention: p63 positive cases in DLBCL (n=32)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: p63 positive cases in T-LBL (n=8)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: p63 positive cases in follicular lymphoma (n=14)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: p63 positive cases in T/NK cell lymphoma (n=6)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: p63 overexpression (above 30%) in DLBCL
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: p63+/p53+ cases
Number of subjects: 126
Study: 12362542

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 1300

Group type: EXPERIMENTAL
Intervention: Single daily injection of low molecular weight heparin
Number of subjects: 1300

Group type: EXPERIMENTAL
Intervention: Warfarin for longer-term secondary prophylaxis
Number of subjects: 1300

Group type: EXPERIMENTAL
Intervention: Combination of clinical probability assessment and D-dimer measurement
Number of subjects: 1300

Group type: EXPERIMENTAL
Intervention: Ultrasonic examination of the leg and CT scan of pulmonary vessels
Number of subjects: 1300
Study: 10211851

Group type: EXPERIMENTAL
Intervention: High force resistance exercise protocol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High power resistance exercise protocol
Number of subjects: 10
Study: 8575688

Group type: EXPERIMENTAL
Intervention: High-dose pure follicle-stimulating hormone (pFSH) (Metrodin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Human menopausal gonadotropin (hMG)
Number of subjects: 0
Study: 2406327

Group type: EXPERIMENTAL
Intervention: Low-dose allergoid (maximal dose: 2000 PNU)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: High-dose allergoid (maximal dose: 10,000 PNU)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 6107548

Group type: EXPERIMENTAL
Intervention: GM1 ganglioside-charcoal
Number of subjects: 46

Group type: COMPARATOR
Intervention: charcoal alone
Number of subjects: 46

Group type: COMPARATOR
Intervention: water
Number of subjects: 46
Study: 30883839

Group type: EXPERIMENTAL
Intervention: Cladribine tablets 3.5 mg/kg
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Cladribine tablets 5.25 mg/kg
Number of subjects: 135

Group type: COMPARATOR
Intervention: Cladribine tablets 3.5 mg/kg and 5.25 mg/kg
Number of subjects: 135
Study: 28333513

Group type: EXPERIMENTAL
Intervention: Client feedback in group psychotherapy
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 159
Study: 26102724

Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg/Hydrochlorothiazide 12.5 mg (NH)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Irbesartan 150 mg/Hydrochlorothiazide 12.5 mg (IH)
Number of subjects: 124
Study: 23916740

Group type: EXPERIMENTAL
Intervention: Extrafin BDP/F 400/24 μg
Number of subjects: 3

Group type: COMPARATOR
Intervention: High dose FP/S 1000/100 μg
Number of subjects: 3

Group type: COMPARATOR
Intervention: Medium dose FP/S 500/100 μg
Number of subjects: 3
Study: 21995901

Group type: EXPERIMENTAL
Intervention: DDD BIV pacing
Number of subjects: 18

Group type: COMPARATOR
Intervention: DDD RV pacing
Number of subjects: 18
Study: 19297655

Group type: EXPERIMENTAL
Intervention: Proposed methodology for estimating parameters of conditional means and variances of gap times
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized trial of asthma prevention
Number of subjects: 0
Study: 16763490

Group type: EXPERIMENTAL
Intervention: efavirenz-containing highly active antiretroviral therapy (zidovudine + lamivudine + efavirenz)
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: efavirenz-containing highly active antiretroviral therapy
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: efavirenz
Number of subjects: 740
Study: 15158606

Group type: EXPERIMENTAL
Intervention: 10 microg of porins (S. typhi outer‐membrane proteins)
Number of subjects: 0
Study: 11275392

Group type: EXPERIMENTAL
Intervention: Amsterdam Pain Management Index
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Pain Education Program
Number of subjects: 313

Group type: COMPARATOR
Intervention: Pain Intensity Markers
Number of subjects: 313

Group type: COMPARATOR
Intervention: Pain Relief Scale
Number of subjects: 313

Group type: COMPARATOR
Intervention: Patient Satisfaction Scale
Number of subjects: 313

Group type: COMPARATOR
Intervention: Pain Management Indexes
Number of subjects: 313
Study: 9786640

Group type: EXPERIMENTAL
Intervention: Mandibular implant-retained overdentures (mainly implant-borne on a transmandibular implant)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Mucosa-borne overdentures on two cylindric permucosal IMZ implants
Number of subjects: 68

Group type: COMPARATOR
Intervention: Conventional dentures in the mandible
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Mainly implant-borne (TMI) and mucosa-implant-borne (IMZ) implant systems
Number of subjects: 68
Study: 7888419

Group type: EXPERIMENTAL
Intervention: Fluoxetine (120 mg/week, administered biweekly)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 107
Study: 3075383

Group type: EXPERIMENTAL
Intervention: IRS 19 (polyvalent bacterial lysate)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 31361655

Group type: EXPERIMENTAL
Intervention: OTX-101 0.09%
Number of subjects: 1048

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 1048
Study: 28856601

Group type: EXPERIMENTAL
Intervention: Cr-enriched yeast (200 μg of elementary Cr in the morning and 100 μg in the evening)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 27004289

Group type: EXPERIMENTAL
Intervention: Laser-collar-treated implants
Number of subjects: 36

Group type: COMPARATOR
Intervention: Nanosurface-treated implants
Number of subjects: 36
Study: 25710379

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (16 normal-weight men)
Number of subjects: 11
Study: 22045827

Group type: EXPERIMENTAL
Intervention: Polidocanol 0.5%
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Polidocanol 1%
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Polidocanol 3%
Number of subjects: 285

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study: 20684735

Group type: EXPERIMENTAL
Intervention: Skin extensibility measured by suction cup (SC)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Skin consistency measured by soft tissue stiffness meter (STSM)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Clinical tests for skin extensibility
Number of subjects: 31

Group type: COMPARATOR
Intervention: Normal skin extensibility
Number of subjects: 31
Study: 18487901

Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 20

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 20
Study: 15986744

Group type: EXPERIMENTAL
Intervention: Direct neuro-muscular neurotization associated with muscular transfer (latissimus dorsi, triceps, pectoralis major)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Latissimus dorsi transfer
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Triceps transfer
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Pectoralis major transfer
Number of subjects: 54